Table 1

Mutation type distribution in relation to clinical characteristics

Patients	Clinical characteristics	Mutations											Mutations
Patients	Clinical characteristics	G12D	G12V	G12C	G12A	G12S	G12R	G12dup	G13D	G13C	G13V	G13A	Mutations
1691	Gender
	Male	112	92	41	23	20	20	1	68	0	0	1	365	671
	Female	88	79	23	19	16	2	0	75	3	1	0	306	671
1691	Age (years)
	<59	46	41	16	10	7	2	0	20	0	0	0	142	671
	≥60	154	130	48	32	29	7	1	123	3	1	1	529	671
1691	Site*
	Primary	185	159	60	39	35	8	1	128	1	0	1	616	671
	Metastasis	15	14	4	3	0	1	0	15	2	1	0	55	671
543	Neoplastic cells percentage*
	<30%	3	5	1	2	0	0	0	1	0	0	0	12	240
	≥30%	69	56	24	19	9	3	1	45	1	0	1	228	240
1406	Specimens
	Resection	143	139	51	28	24	7	1	105	2	1	1	502	567
	Biopsy	19	13	5	6	3	1	0	17	1	0	0	65	567
1095	Fixation modalities (formalin)
	Buffered	112	96	37	19	23	3	0	71	1	0	0	362	428
	Simple	25	12	5	3	2	1	0	17	1	0	0	66	428
1639	Stage*
	I–III	97	85	28	14	18	3	1	61	0	0	0	307	671
	IV	103	171	67	42	36	9	1	143	0	1	1	364	671

*Correlation between KRAS mutation rate and clinical characteristics show a statistical significance in the case of site (primary vs metastasis, p=0.02), neoplastic cell percentage (≥30% vs <30%, p=0.02) and tumour stage (I–III vs IV, p=0.05).